By Umar Farooq
Pakistani expatriate workers, desperate to obtain a Pfizer/BioNTech or AstraZeneca COVID shot so they can travel to work in Saudi Arabia, stormed a vaccination centre in Islamabad on Monday, witnesses said.
Saudi Arabia, which bars direct travel from Pakistan, has only approved the AstraZeneca, Pfizer, Moderna and Johnson and Johnson vaccines. Anyone arriving without one of those shots is required to quarantine at a cost many Pakistani workers say they cannot afford.
Pakistan has relied extensively on the Sinopharm, CanSinoBio, and Sinovac vaccines donated by ally China. That is a problem for the tens of thousands of Pakistanis who work in Saudi Arabia and contribute $7 billion, or a quarter of the country's total annual remittances.
"There was a big crowd and they broke down these glass doors, because they were worried the vaccine would run out," witness Muhammad Ismail, 31, told Reuters. He pointed out the shattered remnants of the vaccination centre's entrance, where a huge crowd swarmed around a handful of medical staff screening people for the shots.
Other witnesses gave similar accounts, but asked not to be named. They estimated the size of the crowd at hundreds.
"The Saudis say they don't want the Chinese vaccine, they want these other ones," said Ismail, who has a job in a restaurant in Saudi Arabia. "Otherwise they keep you in quarantine, and that costs around 5,000 riyal ($1,333.23). My monthly wages are 1,800 riyal, so how can I afford that?"
He and four relatives travelled to Islamabad hoping to get the AstraZeneca vaccine and finally return to their jobs. They have been stuck in Pakistan for the last 9 months after Saudi Arabia told foreign workers to leave late last year.
Earlier this month Pakistan began allowing people under 40 who have to travel for jobs abroad to obtain the AstraZeneca vaccine, of which the country has 1.2 million doses obtained through COVAX.
Pakistan also has around 100,000 doses of Pfizer, meant for immunocompromised people, and the government has said it plans to purchase 13 million more doses by the end of the year.
